How are energy investors positioned?
BILLERICA, Mass. - Bruker Corporation (NASDAQ: BRKR), a $5.6 billion scientific instruments manufacturer currently trading near its 52-week low, has made a significant move in the applied markets by acquiring a majority stake in RECIPE, a manufacturer of diagnostic assays, and introducing the timsMetabo™ platform for advanced small molecule analysis. According to InvestingPro data, the company has demonstrated strong performance with 14.8% revenue growth over the last twelve months. These efforts were highlighted at the 73rd American Society for Mass Spectrometry (ASMS) Conference, held on June 1-5, 2025, in Baltimore, Maryland.
The investment in RECIPE enhances Bruker’s capabilities in therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis. The collaboration between the two companies has led to the integration of RECIPE’s ClinMass® and ClinDART® assay kits with Bruker’s EVOQ® DART-TQ™ system. These kits are designed to offer high-throughput, chromatography-free assays, which are not yet US-FDA approved but may be used in laboratory-developed testing (LDT) approaches. The ClinDART® kits, currently for Research Use Only (RUO), aim to increase lab productivity and reduce solvent use.
In parallel, Bruker has launched the timsMetabo™ platform, which marks a significant advancement in small molecule analysis. The platform incorporates trapped ion mobility spectrometry (TIMS), Mobility Range Enhancement (MoRE), and the Athena Ion Processor (AIP). In early studies, timsMetabo™ demonstrated the ability to identify 40% more low-mass molecules in water samples than previous-generation systems. This technology is particularly relevant for detecting per- and polyfluoroalkyl substances (PFAS) and has potential applications in toxicology and forensic science.
Dr. Gernot Wolfram, Managing Director of RECIPE, commented on the integration of RECIPE’s assay expertise with Bruker’s instrumentation, highlighting the potential for efficient, robust, and sustainable high-throughput workflows in clinical settings.
Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry, emphasized the importance of these developments in redefining the capabilities in applied markets, especially for TDM and environmental analysis. The company’s overall financial health is rated as GOOD by InvestingPro, which has identified multiple growth catalysts. Subscribers can access 6 additional ProTips and comprehensive analysis in the Pro Research Report, offering valuable insights for investors tracking Bruker’s expansion in the applied markets.
Bruker Applied MS plans to further develop solutions for PFAS analysis, forensic toxicology, and TDM. Future applications of the timsMetabo™ platform could include low-mass drug metabolites and emerging contaminants, while RECIPE’s assay pipeline is expected to bolster Bruker’s offerings in the applied market. With net income expected to grow this year and the stock currently trading below its InvestingPro Fair Value, investors may find Bruker’s expansion strategy particularly interesting.
This article is based on a press release statement from Bruker Corporation.
In other recent news, Bruker Corporation announced the acquisition of biocrates life sciences ag, an Austrian company known for its metabolomics kits and services, to strengthen its multiomics strategy. The acquisition aims to enhance Bruker’s capabilities in metabolomics, adding to its existing portfolio in proteomics. Additionally, Bruker unveiled several new mass spectrometry systems at the 73rd Conference on Mass Spectrometry and Allied Topics. The timsUltra AIP mass spectrometer, featuring Athena Ion Processor technology, promises significant improvements in peptide and protein identifications, benefiting research in fields like immunopeptidomics and single-cell proteomics.
Furthermore, Bruker introduced the timsOmni system, which offers comprehensive insights into proteoforms and is expected to be valuable for drug discovery and biologics quality control. The company also launched the timsMetabo system, designed to enhance small molecule analysis with its 4D-Metabolomics technology, improving sensitivity and separation power. In the dairy industry, Bruker released the MOVE-T liquid dairy analyzer, which uses FT-NIR technology for enhanced quality control, aiming to improve product quality and consistency. These developments reflect Bruker’s ongoing commitment to innovation and its efforts to provide advanced scientific instruments for various research and industrial applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.